RCM
IRD

Regency Capital Management’s Opus Genetics IRD Stock Holding History

Regency Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Sell
58,000
-10,000
-15% -$46.6K 0.09% 61
2026
Q1 		$309K Buy
68,000
+22,000
+48% +$76.1K 0.14% 57
2025
Q4 		$92.5K Buy
+46,000
New +$93.4K 0.04% 61
2021
Q4 		– Sell
-15,000
Closed -$60.1K – 174
2021
Q3 		$77K Hold
15,000
– – 0.05% 79
2021
Q2 		$79K Sell
15,000
-2,000
-12% -$9.93K 0.06% 76
2021
Q1 		$99K Buy
+17,000
New +$158K 0.1% 80

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Regency Capital Management's IRD Position: Q2 2026 in Review

Regency Capital Management reduced its Opus Genetics (IRD) stake by 15% in Q2 2026, selling an estimated $46.6K and leaving 58,000 shares worth $238K. The position accounts for 0.09% of the portfolio, ranked #61.

Regency Capital Management first reported a position in IRD in Q1 2021 and has held it in 6 quarters since. The position peaked at $309K in Q1 2026. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Regency Capital Management held 58,000 shares of Opus Genetics worth $238K as of Q2 2026.
  • Regency Capital Management sold 10,000 Opus Genetics shares in Q2 2026, an estimated $46.6K.
  • Opus Genetics made up 0.09% of Regency Capital Management's portfolio in Q2 2026, its #61 holding.
  • Regency Capital Management first reported a position in Opus Genetics in Q1 2021 and has held it in 6 quarters since.
  • Regency Capital Management's Opus Genetics position peaked at $309K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Regency Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.